Compare Citius Pharmaceuticals Inc (CTXR) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Marsh & McLennan Companies, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Marsh & McLennan Companies, Inc. trades at $175.76 (market cap $84.31B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 6190.2× Citius Pharmaceuticals Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.24% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Marsh & McLennan Companies, Inc. for 109 Days on average.
| CTXR | MRSH | |
|---|---|---|
Market Cap | $13.62M | $84.31B |
Volume | 132,438 | 3,948,947 |
Sector | Health | Financials |
52-Week High | $1.82 | $207.02 |
52-Week Low | $0.48 | $157.32 |
Typical Hold Time | 17 Days | 109 Days |
Enterprise Value | $3.79M | $104.99B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
Marsh (MRSH) trades at $176.67, up 1.73% today, with a bullish technical trend and strong support at $174. The company shows robust fundamentals, with revenue growing to $26.98B in 2025 and a net income margin of 14.24%. Recent acquisition of Accel Holdings (Business Wire, 2026-10-02) may enhance growth. Earnings have consistently beaten estimates in recent quarters, with Q3 2026 results pending.
Outlook is positive with a consensus price target of $202.71 (MarketBeat, 2026-09-30), offering ~15% upside. Risks include competitive pressures and market volatility. Analyst sentiment is mixed, with 32% buy ratings but 65% hold, suggesting cautious optimism amid solid execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
